Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Drop in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 49,600 shares, a decrease of 41.7% from the August 31st total of 85,100 shares. Approximately 3.1% of the company’s shares are short sold. Based on an average trading volume of 1,250,000 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 1,250,000 shares, the short-interest ratio is currently 0.0 days. Approximately 3.1% of the company’s shares are short sold.

Sonoma Pharmaceuticals Stock Performance

SNOA opened at $4.40 on Tuesday. The firm has a 50 day moving average price of $4.15 and a 200 day moving average price of $3.44. The company has a market cap of $7.23 million, a PE ratio of -1.79 and a beta of 1.46. Sonoma Pharmaceuticals has a 1 year low of $1.75 and a 1 year high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.14. Sonoma Pharmaceuticals had a negative net margin of 23.87% and a negative return on equity of 50.00%. The company had revenue of $4.01 million during the quarter, compared to the consensus estimate of $4.26 million. On average, sell-side analysts predict that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

SNOA has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sonoma Pharmaceuticals in a report on Saturday, September 27th. Wall Street Zen raised shares of Sonoma Pharmaceuticals to a “hold” rating in a research report on Friday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Sonoma Pharmaceuticals currently has a consensus rating of “Sell”.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.